CION Ameerpet
Understanding the Numbers · Reviewed by CION Oncologists · NABH Accredited
Survival by Stage — What the Numbers Actually Mean
This is the first thing almost everyone searches for and the thing most likely to mislead them. Survival statistics describe what happened to large groups of women diagnosed several years ago. They do not describe you, and they cannot. They also lag current treatment badly — the figures you will find predate molecular classification and immunotherapy, both of which changed outcomes for defined groups. This page is deliberately about how to read these numbers rather than a table of them, because a figure understood is useful and a figure misread does real damage.
- They describe groups, not individuals — and cannot be converted into a personal prediction
- They lag current treatment — five-year data necessarily describes women treated years ago
- Relative survival is not cure — it is a comparison, and a useful one only for comparing groups
- We do not publish a CION figure — Indian endometrial data is limited and we will not invent one
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Five Things to Check Before Believing a Figure
Almost every misleading survival statistic fails at least one of these tests.
| Check | Why it matters |
|---|---|
| What is it measuring? | “Five-year relative survival” compares women with the diagnosis against women of the same age without it. It is not a cure rate, and it says nothing about what happens in year six. It is designed for comparing groups, not for predicting individuals. |
| Over what period were they diagnosed? | Five-year survival necessarily describes women diagnosed at least five years before the data was compiled — and usually longer, since registries lag. In endometrial cancer that predates routine molecular classification and immunotherapy for mismatch repair deficient disease. |
| How are the groups defined? | Registry data usually reports localised, regional and distant rather than FIGO stage numbers. A figure labelled “stage 3” from a registry source may not mean what your report means. |
| What is being averaged together? | A single figure for a stage averages across low-grade endometrioid and serous carcinoma, across POLE-mutated and p53-abnormal tumours, and across women of very different fitness. Those groups behave differently enough that the average describes none of them. |
| Which population? | Most widely quoted figures are from US registry data. Indian registry data specific to endometrial cancer is limited, and outcomes are shaped by stage at presentation and access to treatment as well as by biology. |
Why we do not publish a CION endometrial survival figure. Indian registry data for this cancer specifically is thin, and we would rather say so than print a number we cannot stand behind. Where we quote figures on these pages they are attributed to their source and described as group data. A clinic quoting its own survival rate for a cancer with limited national data is worth questioning.
Did You Know? Endometrial cancer is one of the more favourable common cancers, and the reason is not better treatment — it is earlier detection, achieved without any screening programme at all. Around two thirds of cases in United States registry data are diagnosed while the disease is still confined to the uterus, because the lining bleeds when something is wrong with it and most women act on that. Five-year relative survival for that localised group is high, in the region of 95 per cent. The corollary matters just as much: the women who present late are usually those whose bleeding was dismissed, or who had no bleeding at all. Detection here is a behaviour rather than a test. Sources: SEER (Surveillance, Epidemiology and End Results) Program registry data, US National Cancer Institute; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ICMR National Cancer Registry Programme.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What the Registry Data Broadly Shows
With every caveat above attached, the broad picture from United States registry data is worth stating, because the shape of it is genuinely informative even where the precise numbers are not applicable to any individual.
- Disease confined to the uterus does well. Five-year relative survival in the region of 95 per cent for localised disease — among the more favourable figures in solid tumour oncology, and the group that most women with this diagnosis fall into.
- Regional spread is intermediate. Meaningfully lower than localised disease, and still substantially better than most people assume when they hear that cancer has reached lymph nodes. Treatment at this stage is given with the aim of cure.
- Distant disease is considerably lower. And this is the figure that has changed most since the data was collected, because immunotherapy for mismatch repair deficient disease and combination targeted treatment arrived after most of these women were treated.
- The shape matters more than the numbers. Earlier is better, by a large margin, and that is the actionable message — it is why reporting bleeding promptly matters so much. See postmenopausal bleeding.
Want to Understand Your Own Position?
Stage, grade, depth of invasion and molecular group together tell you far more than any published figure.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Statistic Describes a Population. You Are Not One.
The useful conversation is about your own pathology, and it is a different conversation entirely.
What Actually Moves the Outlook Within a Stage
Two women with the same stage can have quite different situations, and these are the factors that separate them. This is why a stage-based figure tells you so little.
- Histological type. A serous carcinoma and a low-grade endometrioid tumour at the same stage are different diseases. See Type 2 endometrial cancer.
- Grade. Grade 3 behaves considerably less favourably than Grade 1, even at identical stage. See endometrial cancer grades.
- Molecular group. The newest and, in some cases, the most decisive. A POLE-mutated tumour does remarkably well even when it looks aggressive; a p53-abnormal tumour does poorly even when the stage appears modest. See MMR and MSI testing.
- Lymphovascular space invasion. An independent predictor that sits outside the stage entirely in older staging systems.
- Whether treatment was complete. Adequate surgery, appropriate adjuvant treatment and completed follow-up all shape outcome and none of them appear in a stage number. See the adjuvant decision.
- Your general health. Which determines what treatment can be given and tolerated, and is one of the stronger predictors in practice.
This is precisely why the 2023 FIGO revision folded histological type, lymphovascular invasion and molecular group into the staging system — because stage alone was separating outcomes badly. See FIGO staging explained and what affects prognosis.
Want an Honest Conversation About Your Own Outlook?
Based on your pathology rather than a published average — including where you sit within your stage. The opinion is free.
How to Use These Figures Without Being Harmed by Them
Four practical positions that women who have been through this tend to arrive at eventually, and which are worth arriving at sooner.
Decide whether you want the numbers at all
Some women find statistics grounding and others find them corrosive, and both responses are legitimate. You are entitled to say to your oncologist that you would rather not discuss figures, or that you want them in full. Neither position is denial or morbidity. What is worth avoiding is absorbing numbers by accident from search results, which is how most people encounter them and the worst way to do it.
Ask for your own risk, not the population figure
An oncologist who holds your full pathology can speak to your situation in a way no published table can — including whether you sit at the favourable or unfavourable end of your stage. They will not give you a personal percentage, because nobody honestly can, but "your situation is at the more favourable end of that group, and here is why" is a genuinely different and more useful piece of information.
Distrust figures without a date and a source
A survival percentage floating free of when the data was collected and where it came from is not information. In endometrial cancer specifically, figures predating routine molecular classification and immunotherapy describe a different treatment era, and that gap is widest exactly where the numbers look worst — in advanced disease.
Remember what the statistics cannot see
They cannot see your molecular group, whether your surgery was complete, whether you completed adjuvant treatment, or how well you are otherwise. Registry data is coarse by necessity. Being at the favourable end of every one of those factors places you somewhere a stage-based average simply does not describe.
Why We Will Not Print a Number We Cannot Stand Behind
Indian endometrial registry data is limited. Saying so is more useful than manufacturing a figure.
Tumour board for every diagnosis
MMR / MSI testing as standard
Slides reviewed, not just the summary line
45-minute consultations
Second opinions welcomed, not resented
Decisions for healing, not billing
Take The Next Step
Ask About Your Case, Not the Average
Your pathology says considerably more about your position than any published table can.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Survival by Stage — Frequently Asked Questions
What is the survival rate for endometrial cancer?
It depends heavily on how far the disease had spread at diagnosis, and any single figure conceals more than it reveals. United States registry data indicates five-year relative survival in the region of 95 per cent for disease still confined to the uterus, which is where around two thirds of cases are found, with meaningfully lower figures for regional spread and considerably lower for distant disease. But these are group statistics describing women diagnosed years ago, they average across histological types and molecular groups that behave very differently, and they predate treatments that have since changed outcomes for defined groups. They cannot predict what will happen to any individual.
What does "five-year relative survival" actually mean?
It compares women diagnosed with the cancer against women of the same age in the general population, and expresses the proportion still alive after five years relative to what would have been expected without the diagnosis. Two things follow. It is not a cure rate — some women in that surviving group still have disease, and others are entirely well. And it says nothing about year six onwards; a five-year figure is a snapshot, not an endpoint. The measure exists to compare groups fairly across different ages and time periods, which it does well. Using it to answer "how long have I got" is misusing it.
Why do these statistics lag behind current treatment?
Because a five-year survival figure necessarily describes women diagnosed at least five years before the data was compiled, and registries typically lag further still. In endometrial cancer that gap is unusually consequential. Most published figures describe cohorts treated before molecular classification became routine, before checkpoint immunotherapy was available for mismatch repair deficient disease, and before combinations of immunotherapy with targeted treatment entered use in advanced disease. Those developments changed outcomes materially for defined groups of women. The lag matters most precisely where the numbers look worst — in advanced and metastatic disease.
Why does CION not publish its own survival figures for endometrial cancer?
Because Indian registry data specific to endometrial cancer is limited, and we would rather say that plainly than publish a figure we cannot properly support. Where we quote survival data on these pages it is attributed to its source, described as group data, and accompanied by the caveats that make it interpretable. A single-centre survival rate for a cancer with thin national comparison data is difficult to interpret and easy to present misleadingly. If a clinic quotes you its own survival percentage for this disease, it is reasonable to ask what population it is drawn from and over what period.
What tells me more than a stage-based survival figure?
Your own pathology, read as a whole. Stage is one input among several: histological type, tumour grade, depth of invasion into the muscle wall, whether lymphovascular spaces were involved, and molecular group all shape outcome independently — which is exactly why the 2023 FIGO revision folded several of them into the staging system. A POLE-mutated tumour does remarkably well even at high grade; a p53-abnormal tumour does poorly even at modest stage. Beyond the pathology, whether your surgery was complete, whether appropriate adjuvant treatment was given, and your general health all matter and appear in no published table.
Medical disclaimer: This page explains how to interpret endometrial cancer survival statistics and is reviewed by a CION oncologist. Figures referred to are drawn from US SEER registry data, describe groups of women diagnosed several years previously, and predate several treatments now in use. They do not predict the outcome for any individual. Indian registry data specific to endometrial cancer is limited and CION does not publish an endometrial survival figure. Discuss your own situation with the oncology team holding your full pathology.